معرفی
Risto Renkonen serves as a Professor in Chemistry and Microbiology within the Department of Bacteriology and Immunology at the University of Helsinki's Faculty of Medicine. He acts as a Supervisor in the Doctoral Programme in Biomedicine and maintains an active research profile with 248 publications and 10 ongoing projects, including significant EU-funded initiatives running through 2027-2028. His work is centered at the Helsinki University Hospital (HUS) and involves extensive collaboration with both academic and industry partners across Finland and internationally.
Professor Renkonen's research spans multiple domains of biomedical science with particular emphasis on glycoproteomics, inflammation research, and comorbidity analysis. His work integrates advanced proteomic techniques with clinical applications, focusing on biomarker discovery for various conditions including obesity, cancer, transplantation outcomes, and respiratory diseases. His approach combines cutting-edge quantitative proteomics with data-driven methodologies to uncover disease mechanisms and develop predictive models for clinical applications.
Analysis of his recent publications reveals a strong trend toward data-driven approaches in biomedicine, with increasing integration of machine learning techniques with proteomic data. His work bridges basic science and clinical applications, particularly in cancer research, transplantation medicine, and chronic inflammatory conditions. The research demonstrates a consistent focus on identifying biomarkers that can predict disease progression, treatment response, and clinical outcomes across multiple medical specialties.
- Hgin yo hopeinen mitali (August 12, 2010)
- Duodecim Lauri Saxen mitali (August 12, 2010)
- Medix palkinto (September 6, 2010)
Professor Renkonen actively supervises doctoral students in the Biomedicine program and has served as a dissertation supervisor or co-supervisor. His research is supported by diverse funding sources including EU funding through the Uusimaa Federation, Business Finland, corporate partnerships with pharmaceutical companies (AstraZeneca, Pfizer, Orion), and TILT Biotherapeutics. His projects demonstrate strong translational potential with clear pathways to clinical applications. The Veturi_BF_100K_Cancer project (2025-2027) exemplifies his industry-academic collaboration model, bringing together multiple pharmaceutical partners to advance cancer research.
His research activities connect with multiple laboratories and teams across the University of Helsinki and Helsinki University Hospital, with particular emphasis on proteomics and glycoproteomics facilities. The research network extends to international collaborators and includes partnerships with Aalto University, the University of Eastern Finland, and Turku University through the SPARK Finland initiative. His work on the AirGOs2 project demonstrates collaboration with multiple European research groups focused on airway inflammation research.
